Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
28.96 USD -3.47% Intraday chart for Supernus Pharmaceuticals, Inc. -6.07% +0.07%
May. 08 Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M MT
May. 08 Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,244 1,326 1,551 1,928 1,581 1,592 - -
Enterprise Value (EV) 1 1,262 1,326 1,551 1,928 1,581 1,592 1,592 1,592
P/E ratio 11.3 x 10.7 x 29.8 x 34.3 x 1,447 x 116 x -39.1 x 37.6 x
Yield - - - - - - - -
Capitalization / Revenue 3.17 x 2.55 x 2.67 x 2.89 x 2.6 x 2.64 x 2.54 x 2.25 x
EV / Revenue 3.17 x 2.55 x 2.67 x 2.89 x 2.6 x 2.64 x 2.54 x 2.25 x
EV / EBITDA - 6.91 x 13.1 x 15 x 16.2 x 13.6 x 12.9 x 9.22 x
EV / FCF 8.86 x 9.82 x 12.4 x 16.6 x - 18.3 x 14.8 x 10.1 x
FCF Yield 11.3% 10.2% 8.07% 6.04% - 5.48% 6.75% 9.92%
Price to Book 2.09 x - - - - - - -
Nbr of stocks (in thousands) 52,463 52,685 53,181 54,058 54,633 54,974 - -
Reference price 2 23.72 25.16 29.16 35.67 28.94 28.96 28.96 28.96
Announcement Date 2/25/20 2/25/21 4/13/22 2/28/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 392.8 520.4 579.8 667.2 607.5 604 627 707.2
EBITDA 1 - 191.8 118.6 128.8 97.3 117 123 172.8
EBIT 1 148.6 173.7 86.03 46.12 125.1 108.2 120.6 175.1
Operating Margin 37.83% 33.38% 14.84% 6.91% 20.59% 17.91% 19.23% 24.75%
Earnings before Tax (EBT) 1 147.5 168.6 73.18 60.74 2.769 11.64 -33.92 35.82
Net income 1 113.1 127 53.42 60.71 1.316 14.2 -41.9 44.24
Net margin 28.79% 24.39% 9.21% 9.1% 0.22% 2.35% -6.68% 6.26%
EPS 2 2.100 2.360 0.9800 1.040 0.0200 0.2500 -0.7400 0.7700
Free Cash Flow 1 140.4 135 125.1 116.4 - 87.2 107.4 157.9
FCF margin 35.75% 25.93% 21.57% 17.45% - 14.44% 17.13% 22.33%
FCF Conversion (EBITDA) - 70.35% 105.44% 90.42% - 74.53% 87.31% 91.4%
FCF Conversion (Net income) 124.18% 106.3% 234.13% 191.75% - 614.08% - 356.91%
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 2/25/21 4/13/22 2/28/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 159 152.5 170.1 177.4 167.3 153.8 135.6 153.9 164.3 143.6 149.5 155.9 155 147.3 158.6
EBITDA 1 - 22.61 31.99 19.12 55.03 25.14 2.521 29.38 40.26 16.98 32.57 34.26 32.25 43.3 42.1
EBIT 1 6.098 1.967 11.35 -1.523 34.33 30.5 10 8.138 47.1 22.3 25.38 29.36 31.12 27.1 30.65
Operating Margin 3.83% 1.29% 6.67% -0.86% 20.52% 19.84% 7.38% 5.29% 28.66% 15.52% 16.98% 18.83% 20.08% 18.4% 19.33%
Earnings before Tax (EBT) 1 2.051 14.72 11.32 -0.444 35.14 9.017 -17.13 9.889 0.99 0.243 2.381 8.376 0.641 - -
Net income 1 2.442 25.62 7.865 1.749 25.48 16.95 -0.831 -15.98 1.175 0.124 2.94 10.34 0.792 - -
Net margin 1.54% 16.8% 4.63% 0.99% 15.23% 11.02% -0.61% -10.38% 0.72% 0.09% 1.97% 6.63% 0.51% - -
EPS 2 0.0400 0.4300 0.1400 0.0300 0.4300 0.2900 -0.0200 -0.2900 0.0200 - 0.0500 0.1800 0.0100 - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 4/13/22 5/9/22 8/4/22 11/8/22 2/28/23 5/9/23 8/8/23 11/8/23 2/27/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 17.3 - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 140 135 125 116 - 87.2 107 158
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 11.30 - - - - - - -
Cash Flow per Share 2.660 - - - - - - -
Capex 1 2.74 3.45 2.05 0.41 - 4 4.25 7
Capex / Sales 0.7% 0.66% 0.35% 0.06% - 0.66% 0.68% 0.99%
Announcement Date 2/25/20 2/25/21 4/13/22 2/28/23 2/27/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
28.96 USD
Average target price
40.67 USD
Spread / Average Target
+40.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+0.07% 1.59B
MERCK KGAA Stock Merck KGaA
+7.91% 72.81B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.64% 9.13B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.56% 5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+58.79% 4.99B
YUHAN CORPORATION Stock Yuhan Corporation
+4.07% 3.9B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-16.90% 2.48B
INDIVIOR PLC Stock Indivior PLC
+20.84% 2.42B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-26.13% 2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+19.31% 2.17B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. Financials Supernus Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW